drugset / Trial / NCT05188170
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Phase 1
Recruiting
16 enrolled
Stanford University
CURE Childhood Cancer, Inc. · collabPediatric Cancer Research Foundation (PCRF) · collabThe Leukemia and Lymphoma Society · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.
Timeline
- Start
- 2022-11-21
- Primary completion
- 2026-07
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niclosamide | Unknown | 250 mg/m2 | Oral |
| Subject | Niclosamide | Unknown | 500 mg/m2 | Oral |
| Subject | Niclosamide | Unknown | 800 mg/m2 | Oral |
| Subject | Niclosamide | Unknown | 1200 mg/m2 | Oral |